

## DAFTAR PUSTAKA

1. WHO(2021).Hypertension.World Health Organization. <https://www.who.int/news-room/fact-sheets/detail/hypertension> Diakses Oktober 2021.
2. Kementerian Kesehatan RI. Riset Kesehatan Dasar Provinsi Sumatera Barat Tahun 2018. Laporan Riskesdas Nasional 2018; 2018. p. 118-27 .
3. Hari Jantung Sedunia (HJS) Tahun 2019 : Jantung Sehat, SDM Unggul .[http://p2ptm.kemkes.go.id/kegiatan-p2ptm/pusat-/hari-jantung\\_sedunia-hjs-tahun-2019-jantung-sehat-sdm-unggul](http://p2ptm.kemkes.go.id/kegiatan-p2ptm/pusat-/hari-jantung_sedunia-hjs-tahun-2019-jantung-sehat-sdm-unggul)Diakses April 2021.
4. Faktor-faktor yang mempengaruhi Self Care Management pada Pasien Cardiovascular Disease. <https://pjhk.go.id/artikel/faktor-faktor-yang-mempengaruhi-self-care-management-pada-pasien-cardiovascular-disease>Diakses April 2021.
5. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur Heart J.* 2013;34(28):2159–219.
6. Starry Homenta Rampengan. Buku Praktis Kardiologi. Cholid Tri Tjahyono, editor. Jakarta: Badan Penerbit FKUI; 2014.p.150–52.
7. Nugraha N, El Rasyid H. Peranan Elektrokardiografi Pada Hipertrofi Ventrikel Kiri. *Hum Care J.* 2020;5(2):465.
8. Georgiopoulou V V., Kalogeropoulos AP, Raggi P, Butler J. Prevention, Diagnosis, and Treatment of Hypertensive Heart Disease. *Cardiol Clin.* 2010;28(4):675–91.
9. Yildiz M, Oktay AA, Stewart MH, Milani R V., Ventura HO, Lavie CJ. Left ventricular hypertrophy and hypertension. *Prog Cardiovasc Dis.* 2020;63(1):10–21.
10. Ginting MN, Andra CA, Nasution AN, Hasan H, Akbar NZ, Siregar AA. Peguero – Lo Presti Criteria from Electrocardiography to Diagnose Left Ventricular Hypertrophy in Patients with Hypertension in Adam Malik Hospital. *Acta Cardiologia Indonesiana.*2019;6(1):29–33.
11. Patted S V, Porwal SC, Ambar SS, Prasad MR, Chincholi AS. Assessment of Peguero Lo-Presti Criteria for Electrocardiographic Diagnosis of LVH in Indian Subjects.*Cardiol Cardiovasc Med.*2018;2(3):65–73.
12. Aronow WS. Hypertension and left ventricular hypertrophy. *Ann Transl Med.* 2017;5(15):5–8.
13. Yu Z, Song J, Cheng L, Li S, Lu Q, Zhang Y, et al. Peguero-Lo Presti criteria for the diagnosis of left ventricular hypertrophy: A systematic review and meta-analysis. *PLoS One.* 2021;16(1 January):1–14.
14. Peguero JG, Lo Presti S, Perez J, Issa O, Brenes JC, Tolentino A. Electrocardiographic Criteria for the Diagnosis of Left Ventricular Hypertrophy. *J Am Coll Cardiol.* 2017;69(13):1694–703.
15. Narita M, Yamada M, Tsushima M, Kudo N, Kato T, Yokono Y, et al. Novel electrocardiographic criteria for the diagnosis of left ventricular hypertrophy

- in the Japanese general population. *Int Heart J.* 2019;60(3):679–87.
16. Indonesia PDSK. Pedoman Tatalaksana Hipertensi pada Penyakit Kardiovaskular. 1<sup>st</sup> ed. Jakarta; 2015.p.4-5
  17. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. *Hypertension.* 2020;75(6):1334–57.
  18. Janardhanan R, Kramer CM. Imaging in hypertensive heart disease. *Expert Rev Cardiovasc Ther.* 2011;9(2):199–209.
  19. Saxena T, Ali AO, Saxena M. Pathophysiology of essential hypertension: an update. *Expert Rev Cardiovasc Ther.* 2018;16(12):879–87.
  20. Nuraini B. Risk Factors of Hypertension. *J Majority.* 2015;4(5):10–9.
  21. Kim E. Barret, Susan M.Barman, Scott Boitano HLB. Fisiologi Kedokteran Ganong.24<sup>th</sup> ed. McGraw-Hill; 2012.p.701-2.
  22. Izzo JL, Gradman AH. Mechanisms and management of hypertensive heart disease: From left ventricular hypertrophy to heart failure. *Med Clin North Am.* 2004;88(5):1257–71.
  23. Díez J. Hypertensive heart disease. *Hypertension.* 2013;153–64.
  24. Díez J, Frohlich ED. A translational approach to hypertensive heart disease.*Hypertension.* 2010;55(1):1–8.
  25. Fortuño MA, Ravassa S, Fortuño A, Zalba G, Díez J.Cardiomycocyte Apoptotic Cell Death in Arterial Hypertension.*Hypertension.* 2001;38:1406-12.
  26. Duprez DA. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: A clinical review. *J Hypertens.* 2006;24(6):983–91.
  27. Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease Bradford C. Berk. *J Clin Invest.* 2007;117(3):568.
  28. Katholi RE, Couri DM. Left ventricular hypertrophy: Major risk factor in patients with hypertension: Update and practical clinical applications. *Int J Hypertens.* 2011;2011:1-7.
  29. Perhimpunan Dokter Spesialis Kardiovaskuler Indonesia. Panduan Praktis Klinis (PPK) dan Clinical Pathway (CP) Penyakit Jantung dan Pembuluh Darah. Jakarta; 2016.p.42–3.
  30. Johannes AS. Diagnosis Dan Tatalaksana Terbaru Pada Dewasa. *Cdk-*274.2019;46(3):172–8.
  31. Uraizee I, Cheng S, Hung CL, Verma A, Thomas JD, Zile MR, et al. Relation of N-terminal Pro-B-Type natriuretic peptide with diastolic function in hypertensive heart disease. *Am J Hypertens.* 2013;26(10):1234–41.
  32. Taylor AL, Wright JT, Pina IL. Heart Disease in Varied Populations. In: Douglas L. Mann, Douglas P, Zipes PL.Braunwald’s Heart Disease : A Textbook of Cardiovascular Medicine. 10<sup>th</sup>.ed. China; 2015.p. 25.
  33. Yandriani R, Karani Y. Patogenesis Hipertrofi Ventrikel Kiri. *J Kesehat Andalas.* 2018;7(Supplement 2):159.
  34. Cacciapuoti F. Molecular mechanisms of left ventricular hypertrophy (LVH) in systemic hypertension (SH) - Possible therapeutic perspectives. *J Am Soc Hypertension.* 2011;5(6):449–55.
  35. Garcia JAD, Incerpi EK. Factors and mechanisms involved in left ventricular

- hypertrophy and the anti-hypertrophic role of nitric oxide. *Arq Bras Cardiol.* 2008;90(6):443–50.
36. Drazner MH. The progression of hypertensive heart disease. *Circulation.* 2011;123(3):327–34.
  37. Barbieri A, Bursi F, Mantovani F, Valenti C, Quaglia M, Berti E, et al. Left ventricular hypertrophy reclassification and death: Application of the Recommendation of the American Society of Echocardiography/ European Association of Echocardiography. *Eur Heart J Cardiovasc Imaging.* 2012;13(1):109–17.
  38. Thaler M. Satu-satunya buku EKG yang Anda perlukan. In: 8th ed. Jakarta: EGC; 2016. p. 10–91.
  39. Hancock EW, Deal BJ, Mirvis DM, Okin P, Kligfield P, Gettes LS. AHA/ACCF/HRS Recommendations for the Standardization and Interpretation of the Electrocardiogram. Part V: Electrocardiogram Changes Associated With Cardiac Chamber Hypertrophy A Scientific Statement From the American Heart Association Electrocardiography . *J Am Coll Cardiol.* 2009;53(11):992-1002.
  40. Amin M Al, Juniati D. Klasifikasi Kelompok Umur Manusia Berdasarkan Analisis Dimensi Fraktal Box Counting Dari Citra Wajah Dengan Deteksi Tepi Canny. *J Ilm Mat.* 2017;2(6):1–10.
  41. Tabel Batas Ambang indeks Massa tubuh (IMT).2019. <http://p2ptm.kemkes.go.id/infographic-p2ptm/obesitas/tabel-batas-ambang-indeks-massa-tubuh-imt> Diakses April 2021.
  42. Dahlan MS. Statistik untuk Kedokteran dan Kesehatan. Jakarta: Salemba Medika; 2012.p. 129.
  43. Ainsyah RW, Farid M, Lusno D, et al. Hubungan Karakteristik dan Status Obesitas Sentral dengan Kejadian Hipertensi. 2018;6:51-9.
  44. Muharam MH, Achmad S, Rahimah S. Karakteristik Usia dan Jenis Kelamin Penderita Hipertensi dengan Kejadian Stroke atau Coronary Artery Disease di Rumah Sakit Umum Daerah Al-Ihsan pada Tahun 2015. 2016;2(2):243-9.
  45. Widiana IMR, Ani LS. Prevalensi dan karakteristik hipertensi pada pralansia dan lansia di Dusun Tengah , Desa Ulakan , Kecamatan Manggis. *E-Jurnal Med.* 2017;6(8):1-5.
  46. Robin GD, Primayanti IDAI, Dinata IMK. Prevalensi Hipertensi Pada Mahasiswa Semester Vi Program Studi Pendidikan Dokter Di Fakultas Kedokteran Universitas Udayana. *E-Jurnal Med Udayana.* 2017;6(2):1-16.
  47. Rahajeng E, Tuminah S. Prevalensi Hipertensi dan Determinannya di Indonesia Prevalensi Hipertensi dan Determinannya di Indonesia. *Pus Penelit Biomedis dan Farm Badan Penelit Kesehat Dep Kesehat RI, Jakarta Abstr.* 2021;1:10-22.
  48. Kurniasih I, Setiawan MR. Analisis Faktor Risiko Kejadian Hipertensi di Puskesmas Sronдол Semarang Periode Bulan September – Oktober 2011. *J Kedokt Muhammadiyah.* 2013;1(2):54-9.
  49. Sedayu B, Azmi S, Rahmatini R. Karakteristik Pasien Hipertensi di Bangsal Rawat Inap SMF Penyakit Dalam RSUP DR. M. Djamil Padang Tahun 2013. *J Kesehat Andalas.* 2015;4(1):65-9.
  50. PERKI. Pedoman Tatalaksana Pencegahan Penyakit Kardiovaskular pada



- Perempuan. *Ed Pertama*. 2015:1-100.
51. Kementerian Kesehatan RI. Laporan Riset Kesehatan Dasar Tahun 2013. Laporan Riskesdas Nasional 2013; 2013. p. 88-90.
  52. Kementerian Kesehatan RI. Laporan Riset Kesehatan Dasar Tahun 2018. Laporan Riskesdas Nasional 2018; 2019. p. 154-63.
  53. Ramdhani R, Respati T, Nia Irasanti S. Karakteristik dan gaya hidup pasien hipertensi di RS Al-Islam Bandung. *Gmhc*. 2013;1:2-5.
  54. Field T. Hypertension Management : The Care Gap. 2017;10(April):481-6.
  55. Putri MPD, Suyasa IPGEA, Budiapsari PI. Hubungan antara Dislipidemia dengan Kejadian Hipertensi di Bali Tahun 2019. *Aesculapius Med J*. 2021;1(1):8-12.
  56. Agabiti-Rosei E, Muiesan ML, Salvetti M. Evaluation of sub clinical target organ damage for risk assessment and treatment in the hypertensive patients: Left ventricular hypertrophy. *J Am Soc Nephrol*. 2006;17(SUPPL. 2):104-8.
  57. Ruilope LM, Schmieder RE. Left ventricular hypertrophy and clinical outcomes in hypertensive patients. *Am J Hypertens*. 2008;21(5):500-8.
  58. Mancía G, Carugo S, Grassi G, et al. Prevalence of left ventricular hypertrophy in hypertensive patients without and with blood pressure control: Data from the PAMELA population. *Hypertension*. 2002;39(3):744-9.
  59. Kuruvilla S, Janardhanan R, Antkowiak P, et al. Increased extracellular volume and altered mechanics are associated with LVH in hypertensive heart disease, not hypertension alone. *JACC Cardiovasc Imaging*. 2015;8(2):172-80.
  60. Bornstein AB, Rao SS, Marwaha K. Left Ventricular Hypertrophy.. StatPearls Publishing; 2022 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK557534/>. *StatPearls [Internet] Treasure Isl*. 2022. <https://www.ncbi.nlm.nih.gov/books/NBK557534/>.
  61. Decramer M, Janssens W, Miravittles M. Chronic obstructive pulmonary disease. *Lancet*. 2012;379(9823):1341-51.
  62. Sun GZ, Wang HY, Ye N, Sun YX. Assessment of Novel Peguero-Lo Presti Electrocardiographic Left Ventricular Hypertrophy Criteria in a Large Asian Population: Newer May Not Be Better. *Can J Cardiol*. 2018;34(9):1153-7.